What is Eptifibatide?
Eptifibatide (brand name INTEGRILIN, development code SCH-60936) is a cyclic heptapeptide antagonist of the platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor. It was approved by the FDA on May 18, 1998 for treatment of acute coronary syndrome (ACS) and as adjunct anticoagulation during percutaneous coronary intervention (PCI).
Eptifibatide is derived from a peptide motif found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). The natural snake peptide barbourin contains a unique KGD (lysine-glycine-aspartate) motif that selectively antagonizes platelet GPIIb/IIIa without binding the related αvβ3 vitronectin receptor. Eptifibatide is a synthetic cyclic peptide engineered from this motif.
Structure and Origin
Native barbourin: a disintegrin from rattlesnake venom that prevents prey from clotting.
Eptifibatide structure:
- Cyclic disulfide-bridged heptapeptide
- Contains the KGD recognition motif (modeled after barbourin's selectivity)
- Mercaptopropionic acid (Mpr) at position 1 forms the cyclizing disulfide with cysteine at position 7
- Homoarginine and tryptophan substitutions optimize receptor affinity and stability
The KGD motif provides selectivity for GPIIb/IIIa over the structurally related αvβ3 receptor — important for limiting off-target effects.
Mechanism of Action
GPIIb/IIIa is a platelet integrin receptor that is the final common pathway of platelet aggregation:
- When platelets are activated by thrombin, ADP, collagen, or other agonists, GPIIb/IIIa undergoes conformational change
- Activated GPIIb/IIIa binds fibrinogen, which cross-links adjacent platelets
- This bridging is the molecular basis of platelet aggregation
Eptifibatide binds activated GPIIb/IIIa, preventing fibrinogen binding and blocking platelet aggregation. Because it acts at the final pathway, it suppresses platelet aggregation triggered by all upstream agonists, providing comprehensive anti-platelet effect.
Clinical Evidence
PURSUIT (NEJM 1998):
- 10,948 patients with non-ST-elevation ACS
- Eptifibatide infusion vs placebo on top of aspirin and heparin
- Reduced 30-day composite endpoint of death or non-fatal MI (14.2% vs 15.7%, p=0.04)
- Established eptifibatide as effective in ACS
ESPRIT (Lancet 2000):
- Eptifibatide as adjunct to PCI
- Reduced 48-hour ischemic complications
Approval History
- May 18, 1998 — FDA approval for ACS and PCI
- Generic eptifibatide approvals from 2015 onward
- Remains in clinical use, though use has declined with the rise of more potent oral P2Y12 inhibitors (ticagrelor, prasugrel)
Place in Therapy
Eptifibatide's role has narrowed with evolving practice:
- Bailout in PCI — for thrombotic complications during the procedure
- High-risk ACS undergoing PCI — when oral antiplatelet loading is inadequate
- Largely supplanted by oral P2Y12 inhibitors and selective use of bivalirudin for routine PCI
It remains a useful tool when rapid, complete platelet aggregation blockade is needed.
Safety Profile
The dominant safety concern is bleeding:
- Major bleeding requiring transfusion
- Access-site bleeding in PCI
- Thrombocytopenia (less common than with abciximab)
Eptifibatide is renally cleared, requiring dose adjustment in renal impairment, and is contraindicated in severe renal failure (CrCl <30 mL/min for the maintenance infusion).
Why It Matters
Eptifibatide is a notable example of venom-to-drug development — alongside ziconotide (cone snail), captopril (Brazilian pit viper), and exenatide (Heloderma suspectum saliva). The KGD-selective design principle from barbourin has informed subsequent integrin-targeted drug discovery efforts.